$89 Million

Frequency Therapeutics, Inc.

Initial Public Offering

Bookrunner, October 2019

Frequency Therapeutics, Inc.
Frequency Therapeutics, Inc. is clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The Company’s proprietary approach, called Progenitor Cell Activation, or PCA, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The Company’s lead candidate, FX-322, is being developed to treat the underlying cause of sensorineural hearing loss, or SNHL.